RT @Lupusreference: â #EULAR2022 positive Phase 2 results for #deucravacitinib (TYK2 inhibitor) in systemic #Lupus wit
Tweet Content
✅ #EULAR2022 positive Phase 2 results for #deucravacitinib (TYK2 inhibitor) in systemic #Lupus with SRI(4) at 32W:
- DEU 3mg BID: 58.2% (p=0.0006)
- DEU 6mg BID: 49.5% (p=0.021)
- DEU 12mg QD: higher (but NS)
vs Placebo 34.4%
+ secondary endpoints.
https://t.co/QCWqW97tre
Links
Bristol Myers Squibb - Late-Breaking Data at EULAR 2022 Demonstrate Deucravaci…
https://news.bms.com/news/details/2022/Late-Breaking-Data-at-EULAR-2022-Demonst…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off